---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-23-000033"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:12:03.636047+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio reports 2022 net loss of $223M; cash runway beyond 2026; ITIL-306 phase 1 in 2H 2023

## Summary
- Cash & marketable securities $260.9M (Dec 31, 2022) vs $454.1M in 2021; cash runway beyond 2026 with <$10M quarterly burn from 2H 2023.
- Net loss $223.2M in 2022 ($1.72/share) vs $156.8M ($1.48/share) in 2021; restructuring charge $23.2M.
- Discontinued ITIL-168 program Dec 2022 over manufacturing issues; prioritized ITIL-306 with anticipated UK MHRA CTA clearance 2H 2023.
- Initial ITIL-306 phase 1 clinical data expected in 2024; consolidated R&D ops to Manchester, UK; seeking lease/sale of Tarzana facility.

## SEC filing metadata
- accession: 0001789769-23-000033
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/til-20230331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-23-000033
- JSON: https://secwatch.observer/filing/0001789769-23-000033.json
- Plain text: https://secwatch.observer/filing/0001789769-23-000033.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss $ (53,844), EPS Net loss per share, basic and diluted $ (0.41).
  - Period: the fourth quarter ended December 31, 2022
  - Net income: Net loss $ (53,844)
  - EPS: Net loss per share, basic and diluted $ (0.41)
  - Result: reported results
  source text: Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm
- Earnings Releases
  Instil Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss $ (223,177), EPS Net loss per share, basic and diluted $ (1.72).
  - Period: the full year ended December 31, 2022
  - Net income: Net loss $ (223,177)
  - EPS: Net loss per share, basic and diluted $ (1.72)
  - Result: reported results
  source text: Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.